March 10, 2026 · Form 4 insider transaction
Valantine Hannah sold 8,671 shares of BridgeBio Pharma, Inc. at $72.00 per share, a transaction worth $624.3K. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 2 days after the transaction.
This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 14, 2025.